ERS Respiratory Channel

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

Abstract

Background: Interstitial lung disease (ILD) is one of the main causes of death in patients with rheumatoid arthritis (RA), constituting its early diagnosis a challenge for the clinicians [1]. In this regard, endothelin-1 (ET-1), the most potent endogenous vasoconstrictor, has been described as a profibrotic molecule [2].

Objectives: To explore the role of ET-1 as a biomarker of pulmonary fibrosis in RA-ILD⁺.

Methods: 21 RA-ILD⁺ patients and two comparative groups: 25 RA-ILD^- patients and 21 idiopathic pulmonary fibrosis (IPF) patients were included. Serum levels of ET-1 were determined by ELISA.

Results: RA-ILD⁺ patients showed increased levels of ET-1 compared to those with RA-ILD^- (p<0.01). The ability of serum ET-1 levels to discriminate RA-ILD⁺ patients from those with RA-ILD^- was further confirmed by receiver operating characteristic curves (area under the curve: 0.77, p<0.01). The optimal cutoff value for ET-1 showing the best sensitivity and specificity was 1.02pg/mL. Moreover, RA-ILD⁺ patients presented similar levels of ET-1 than those with IPF. A negative correlation between ET-1 levels and both forced vital capacity and forced expiratory volumen at first second was disclosed in RA-ILD⁺ patients (r=-0.56,p=0.04 and r=-0.65,p=0.01, respectively).

Conclusions: Our study suggests that ET-1 levels are linked to lung injury and worse lung function, supporting its role as a potential blood biomarker of ILD in RA patients.

References: [1]Expert Rev Clin Immunol.2021;17(5):485-497;[2]Am J Respir Cell Mol Biol.2010;42(1):16-20.

Personal funds,VP-C:PI18/00042(ISCIII-ERDF);MSM-G:TRANSVAL22/01(IDIVAL);RL-M: CPII21/00004(ISCIII-ESF).

Abstract

#{title}